Research in Focus: Hypertension May Be More Than a Pressure Problem
Written by N. Streawbridge| 29 April 2026
What inflammation resolution is teaching us about vascular damage, arterial stiffness and a possible new therapeutic target
For decades, hypertension has largely been explained through a combination of increased sympathetic nervous system activity, activation of the renin–angiotensin–aldosterone system, altered kidney sodium handling and changes in vascular resistance. These mechanisms remain fundamental.
But research is adding another important layer to the picture: chronic immune activation and, particularly, the failure to properly resolve inflammation may help maintain vascular dysfunction and drive the organ damage associated with hypertension.
A recent experimental study examining a compound called Cmpd17b offers an interesting glimpse into this emerging field.
Inflammation is not simply something that has to be “switched off”.
Inflammation is a normal protective response to tissue injury, infection or metabolic stress. Importantly, however, ending an inflammatory response is not passive. The body actively initiates a highly coordinated resolution programme designed to:
- stop further inflammatory-cell recruitment;
- remove damaged cells and debris;
- change macrophage behaviour;
- promote tissue repair;
- restore vascular and immune homeostasis.
This involves specialised pro-resolving mediators such as resolvins, protectins, maresins and lipoxins, together with other signalling molecules, regulatory immune cells and processes such as efferocytosis — the clearance of dying cells. When these mechanisms do not work effectively, inflammation may fail to return completely to baseline. Instead, tissues can remain in a state of persistent, low-grade inflammatory activation. A growing body of research suggests that this may be particularly relevant in hypertension.
How could unresolved inflammation affect blood pressure?
Hypertension does not develop through a single pathway. Sympathetic nervous system activation, angiotensin II, aldosterone, oxidative stress, metabolic dysfunction and altered kidney sodium handling all interact. Inflammation appears to sit within this network rather than outside it. For example:
Angiotensin II and oxidative stress
↓
immune activation and inflammatory signalling
↓
reduced endothelial nitric oxide availability
↓
poorer vasodilation
↓
increased vascular resistance
At the same time, persistent inflammatory signalling can promote:
vascular smooth-muscle activation → extracellular-matrix deposition → fibrosis → arterial stiffness
A stiffer artery cannot expand as effectively with each heartbeat. This increases the haemodynamic load on the circulation and can contribute particularly to elevated systolic blood pressure.
The process can therefore become self-reinforcing:
high blood pressure → vascular stress → inflammation and remodelling → increasing arterial stiffness → further haemodynamic stress.
A different approach: resolve rather than simply suppress inflammation
This is where the recent research becomes particularly interesting. Researchers studied compound 17b, or Cmpd17b, a small molecule that activates formyl peptide receptors FPR1 and FPR2.
FPRs are G-protein-coupled receptors involved in immune signalling and the regulation of inflammatory resolution. Rather than acting like a conventional anti-inflammatory drug that broadly suppresses inflammatory pathways, Cmpd17b was designed to favour signalling associated with resolution, cell survival and tissue protection.
Researchers tested the compound in mice in which hypertension was induced using angiotensin II.
What did they find?
Cmpd17b produced a moderate reduction in blood pressure.But something more striking happened in the cardiovascular tissues. Compared with untreated hypertensive mice, animals receiving Cmpd17b showed improvements in cardiovascular function accompanied by reductions in:
- cardiac fibrosis;
- aortic fibrosis;
- vascular calcification;
- pathological cardiovascular remodelling.
The treatment also influenced mitochondrial function and altered proteins involved in inflammation, calcium regulation, extracellular-matrix organisation and cardiovascular structure.
Proteomic analysis identified approximately 6,000 proteins, allowing the researchers to examine how hypertension altered entire molecular networks rather than individual biomarkers.
Importantly, some of the protein changes affected by Cmpd17b in mice overlapped with proteins known to be dysregulated in human cardiac hypertrophy and adverse aortic remodelling.
The most interesting finding may not have been the fall in blood pressure
The blood-pressure reduction was relatively modest. Yet the improvement in cardiovascular tissue damage was considerably more pronounced.That distinction matters. It suggests that some of the damage associated with hypertension may not simply be the mechanical consequence of blood pushing too strongly against the arterial wall.
There may be parallel biological processes — inflammation, mitochondrial dysfunction, oxidative stress and abnormal tissue remodelling — that continue contributing to cardiovascular risk even when blood pressure itself is being treated.
An accompanying editorial highlighted precisely this possibility: targeting inflammatory resolution could potentially address some of the residual cardiovascular damage that cannot be explained by blood-pressure reduction alone.
Does this mean scientists have discovered a “third cause” of hypertension?
Not quite. Headlines describing inflammation as a newly discovered “third cause of hypertension” make the research sound more revolutionary — and simpler — than it actually is. Inflammatory and immune mechanisms in hypertension have been studied for years. What is newer and particularly interesting is the shift from asking: “How can we suppress inflammation?” to asking: “Why did the inflammatory response fail to resolve?”
These are biologically different questions. The latter opens the possibility of supporting physiological pathways that actively restore immune and vascular balance rather than chronically blocking inflammatory signalling.
A more complete model of hypertension
Instead of thinking about hypertension as the result of only one or two pathways, contemporary research increasingly supports a network model:
Sympathetic nervous system
↕
RAAS / angiotensin II / aldosterone
↕
Kidney sodium and fluid regulation
↕
Endothelial dysfunction
↕
Oxidative stress
↕
Metabolic dysfunction
↕
Immune activation and impaired inflammation resolution
↓
vasoconstriction + sodium retention + reduced nitric oxide + vascular remodelling
↓
arterial stiffness + cardiac and renal damage
↓
persistent hypertension
Different elements of this network may dominate in different people. This is one reason hypertension should not always be viewed as one disease with one mechanism.
The Wildberry Perspective
This research reinforces an important principle in cardiovascular medicine: lowering the number on the blood-pressure monitor and improving the biological health of the cardiovascular system are closely related — but they are not necessarily identical goals.
Blood-pressure control remains fundamental and proven antihypertensive medicines remain essential when indicated. But cardiovascular health also depends on endothelial function, vascular elasticity, mitochondrial function, metabolic health, kidney regulation, inflammatory signalling and the structural integrity of the vascular wall.
The research on Cmpd17b is still preclinical. It was performed predominantly in an angiotensin-II-induced mouse model of hypertension, and the compound is not an established treatment for human hypertension. We therefore cannot assume that the same benefits will occur in patients.
What the study does provide is an intriguing mechanistic direction. Rather than treating chronic inflammation simply as something to suppress, future cardiovascular therapies may increasingly investigate how to restore the body's ability to complete inflammation and return the tissue to homeostasis.
For herbal medicine, this is also an interesting research question. Medicinal plants are frequently described simply as “anti-inflammatory.” A much more sophisticated question is whether particular phytochemicals can influence resolution biology, endothelial signalling, macrophage phenotype, specialised pro-resolving mediator pathways, oxidative stress and tissue remodelling.
That is a considerably more interesting direction for cardiovascular botanical research than asking whether a plant merely lowers a single inflammatory marker.
References
Singh A, et al. Novel formylpeptide receptor 1/2 agonist limits hypertension-induced cardiovascular damage. Cardiovascular Research. 2024;120(11):1336–1352.
Beyond the numbers in treating hypertensive end-organ damage: role of formyl peptide receptor agonist Cmpd17b. Cardiovascular Research. 2024;120(11):1239–1241.
Resolution of inflammation, an active process to restore the immune microenvironment balance: A novel drug target for treating arterial hypertension. Ageing Research Reviews. 2024;99:102352.
Research in Focus examines emerging scientific research relevant to health and medicinal-plant practice. Experimental findings, particularly studies conducted in animals or laboratory models, should not be interpreted as evidence that an intervention is effective or safe in humans. This article is for educational purposes and does not replace individual medical assessment or treatment.
Recent Posts











